Pain Management in Response to Exparel vs. Standard Bupivicaine

• Status: Completed
• Trial end date: 2017-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is looking to evaluate the efficacy of liposomal bupivicaine (Exparel) on decreasing the amount of consumed pain medications.

Patients will be randomly selected to received either Exparel or standard bupivicaine injection during surgery. Patients will be followed up to assess pain levels using a visual pain scale, and to assess how much pain medication was consumed.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Inova Health Care Services
• Collaborator: Mednax National Medical Group
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• All patients over 18 years of age

• Isolated thoracoscopic procedure for therapeutic or diagnostic purposes

Exclusion Criteria:

• Previous ipsilateral thoracic surgery

• Need for operative pleurectomy or pleurodesis

• Chronic use of pain medication -narcotics or nonsteroidal antiinflammatory drugs (NSAIDs), sedatives, or hypnotics

• Allergies to bupivacaine or other local anesthetics, narcotics, NSAIDs or acetaminophen

• Liver dysfunction (INR > 1.5, albumin < 2.8g/dl, bilirubin > 2mg/dl)

• Renal dysfunction (eGFR < 60ml/min/1.73m2)

• History of peptic ulcerative disease

• Severe chronic obstructive pulmonary disease (COPD) requiring continuous oxygen supplementation

• Inability to consent

• Pregnancy

• Need for conversion from a Video-Assisted Thoracic Surgery procedure to a thoracotomy

• Patient is discharged from the hospital with a chest tube in place

• Patient fails to comply with post-operative instructions